Introduction
============

Cancer represents a major cause of mortality. It accounted for about 7 Mio deaths in 2000 ([@B45]) and 8.2 million deaths in 2012 worldwide ([@B37]). In 2008, 12.7 Mio new cancer cases were estimated ([@B58]). Recently, 1,688,780 new cancer cases and about 600,920 cancer deaths were estimated to occur in the United States ([@B122]). Although, significant progress has been made in cancer therapy during the past years, treatment outcome is still largely hampered by drug resistance and severe side effects ([@B135]). Various mechanisms of anticancer drug resistance have been described, e.g., point mutations in drug targets, drug efflux pumps, xenobiotic detoxification mechanisms, resistance to apoptosis, repair DNA damage, alteration of cell proliferation features and others ([@B22]). For this reason, novel compounds are urgently required for the improvement of treatment outcomes and survival prognosis of patients ([@B135]).

Arsenic is a semimetal naturally existing in earth, water and air. It is found in many chemical forms such as yellow arsenic (As~2~S~3~), red arsenic (As~2~S~2~), white arsenic (As~2~O~3~) etc. ([@B96]). Since ages, As~2~O~3~ is used in traditional Chinese medicine. In the 1970s, Chinese scientists tested the potential of As~2~O~3~ to treat acute PML ([@B110]). Today, As~2~O~3~ is clinically used worldwide to treat APL and multiple myeloma ([@B123]; [@B12]; [@B56]). A major driver of tumorigenesis of APL is the *PML/RARA* oncogene. Interestingly, As~2~O~3~ targets this oncogene, which explains its strong activity in this tumor entity. In combination with retinoic acid, As~2~O~3~ can cure up to 90% of APL patients ([@B73]). After binding of As~2~O~3~ to PML/RARA, sumoylation and ubiquitination takes place. Further events included in As~2~O~3~'s modes of action include reactive oxygen species generation, inducing apoptosis and cell cycle arrest, activating caspases 8 and 9, down-regulating VEGF thus suppress the angiogenesis as well as inhibition of tumor invasion and metastasis ([@B147]; [@B54]; [@B104]; [@B111]; [@B4]; [@B50]; [@B83]).

Independent from the activity of As~2~O~3~ in APL, other tumor types may also be affected via other mechanisms, e.g., the hedgehog signaling pathway in medulloblastoma ([@B8]; [@B65]), indicating that the full range of mechanisms of As~2~O~3~ has not been elucidated yet.

Recently, network pharmacology becomes an important bioinformatics tools for identifying the mechanism of action of traditional Chinese medicine (TCM). Several methodologies including proteomics, metabolomics, genomics and serum pharmacokinetics are used to identify molecular target and mechanisms of TCM formulas. Applying this methods will lead to a shift from one drug- one target model to network target-multi-components models ([@B79]). In addition, applying network analysis (protein--protein interaction) may identify drug-target-related proteins ([@B78]).

In an endeavor to study the cytotoxic activity of As~2~O~3~ in cell lines of other tumor types than APL and to identify possible novel modes of action, we undertook the present project. The aims of this study were firstly to investigate whether classical drug resistance mechanisms such as *P*-glycoprotein, the tumor suppressor p53 and the EGFR may decrease cellular responsiveness to As~2~O~3~. The anti-proliferation activity of As~2~O~3~ and predominantly its effects against colon carcinoma resistant cell lines HCT116 (p53^-/-^), U87M. ΔEGFR glioblastoma multiforme cancer cells is reported here for the first time. Furthermore, we performed COMPARE and hierarchical cluster analyses for 58 cell lines of the National Cancer Institute (NCI, United States) from nine different tumor types^[1](#fn01){ref-type="fn"}^. Then, we run bioinformatical gene promoter binding motif analyses for those genes obtained by COMPARE and hierarchical cluster analyses. Since AP-1 and NF-κB binding sites were predominant in the gene promoter sequences subjected to binding motif analyses, we used reporter cell lines for these two transcription factors and indeed observed that As~2~O~3~ inhibited promoter binding of these two transcription factors. Finally, we performed interactome network analysis using IPA software to identify cellular pathways that might be affected upon As~2~O~3~ treatment.

Materials and Methods {#s1}
=====================

Cell Lines and Reagents
-----------------------

We tested cell lines expressing different modes of drug resistance and their corresponding parental, drug sensitive cell lines. These included the leukemia CCRF-CEM (drug sensitive), and the drug resistant CEM/ADR5000 (multidrug resistant), the human glioblastoma U87.MG (wild type) and U87.MG ΔEGFR (mutated type), and the colon carcinoma HCT-116 (p53^+/+^) and HCT-116 (p53^-/-^) cell lines. The details about the cell lines were described previously by our group ([@B114]). Glioblastoma were provided from Dr. W. K. Cavenee (Ludwig Institute for Cancer Research, San Diego, CA, United States). While, colon cancer cell lines were provided by Dr. B. Vogelstein and H. Hermeking (Howard Hughes Medical Institute, Baltimore, MD, United States).

Tumor cell lines were routinely cultured in proper medium (Sigma--Aldrich, Taufkirchen, Germany) with 10% FBS (Sigma--Aldrich, Taufkirchen, Germany), 1% penicillin/streptomycin Sigma--Aldrich) ([@B15]; [@B31]). Moreover, doxorubicin (5000 ng/mL) was used to maintain the resistance of CEM/ADR5000 cells ([@B64]). While U87.MG ΔEGFR and HCT-116 (p53^-/-^) was treated with geneticin to maintain expression of the transcript. Cells were incubated at 37°C under 5% CO~2~ in a humidified atmosphere. As~2~O~3~ and geneticin were purchased from Sigma--Aldrich, Germany. Doxorubicin was kindly provided by the University Medical Center, Johannes Gutenberg University (Mainz, Germany).

Cytotoxicity Assays
-------------------

The cytotoxicity of As~2~O~3~ was assessed using the resazurin reduction assay method as previously described ([@B71], [@B72]). Cells were treated with different concentrations of As~2~O~3~, ranging from 0.003 to 500 μM. The assay principle is that resazurin (Sigma--Aldrich) is reduced by viable cells to the highly fluorescent resorufin ([@B99]). Dead cells have no capability to convert resazurin to resorufin which lack the fluorescence property. Infinite M2000 proplate reader (Tecan, Germany) detected the fluorescent signal that emitted by the viable cells. Experiments were done three times, with six replicates for each concentration. The viability of the cells treated with As~2~O~3~ was calculated as percentage in compared with untreated control cells. The obtained cell viability was plotted against As~2~O~3~ concentration using Microsoft Excel 2016. Dose response curve was used to calculate the IC~50~ values of every cell line.

NF-κB Reporter Assay
--------------------

HEK-Blue-Null1 cells were obtained from Invivogen (San Diego, CA, United States). It is derived from embryonic kidney-293 (HEK-293) cell line. HEK-Blue-Null1 cells culture conditions were previously described ([@B62]; [@B118]; [@B47]). Briefly, HEK-Blue-Null1 cells constantly transcribe the SEAP protein under control of the NF-κB promoter. Cells were treated with varying concentrations of As~2~O~3~. NF-κB pathway was activated using 100 ng/mL of TNF and inducted for 24 h. Then, detection using pre-warmed Quanti-Blue reagent (Invivogen) was performed according to the manufacturer's protocol. SEAP was measured spectrophotometrically at 630 nm to detect NF-κB activity. The fold change was calculated in compare with untreated control cells. The NF-κB inhibitor triptolide (1 μM, Invivogen) was used as positive control. The experiments were repeated three times.

AP-1 Reporter Assay
-------------------

HEK293 cells were trypsinized and evenly distributed into 96 well plate polystyrene U96. The cells were then transfected with AP-1 luciferase reporter construct (CCS-011L, Qiagen, Germantown, MD, United States) using Attractene transfection reagent (Promega, Germany) according to the manufacturer's protocols. After 24 h of the transfection process, cells were incubated with different doses of As~2~O~3~. After 18 h of incubation time with As~2~O~3~, AP-1 activation was induced by of 50 ng/ml phorbol 12-myristate 13-acetate PMA (Sigma--Aldrich) for 24 h. AP-1 promoter activity was measured by Dual-Luciferase Reporter Assay System (Promega, Madison, WI, United States) following the manufacturer's recommendations. Both firefly and *Renilla* luciferase luminescences were measured using Infinite M2000 Pro plate reader (Tecan). The firefly luciferase luminescence ratio to *Renilla* luciferase luminescence for each sample was calculated to obtain the relative luciferase. Normalization of AP-1 activity was done using the following equation: relative luciferase of sample over the relative luciferase of the untreated control cells ([@B61]). AP-1 luciferase assay experiments were repeated twice.

Bioinformatical Methods
-----------------------

In the present manuscript, we applied several methods of systems biology. While conventional medicine prefers a reductionist approach with one (or few) targets for an investigational drug, traditional medicine always emphasized the multi-specific nature of natural products ([@B28]). The advent of genome-wide expression profiling techniques was estimated as specifically promising for natural product research, as complex cascades, pathways, and gross gene alteration patterns can be measured in a single experiment ([@B59]; [@B109]; [@B25]; [@B36]). Molecular pharmacology with the investigation of single pathways has been enlarged by the new field of network pharmacology ([@B108]; [@B117]; [@B30]). As myriads of data points are collected with genome-wide methods, the data evaluation requires the application of bioinformatics to uncover relevant biological mechanisms of drugs. The "-omics" technology in conjunction with bioinformatical methods allow the generation of hypothetical predictions that could be tested and verified in experimental and clinical settings.

### COMPARE Analysis

A panel of 58 cell lines from National Cancer Institute (NCI), United States were used to perform COMPARE and hierarchical cluster analyses. Logarithmic IC~50~ values (log~10~IC~50~) of As~2~O~3~ have been deposited at the NCI database^[2](#fn02){ref-type="fn"}^. The mRNA expression values of NCI cell lines were determined via microarray analyses were deposited at the NCI website^2^ as well. These data were used to generate rank ordered lists of genes expressed in the NCI cell lines panel using COMPARE analyses ([@B103]).

To extract the most meaningful results from a non-relevant "background noise" of transcriptome-wide microarray-based mRNA hybridizations, we applied the COMPARE analysis, which has been developed by [@B103] from the NCI (United States). During the past decades, NCI has investigated more than 300,000 compounds for their cytotoxic capability against a panel of 60 cell lines from different tumor origin. The still growing NCI drug repository does not contain only synthetic compounds but also natural products. Paull and his team observed that drugs with similar molecular modes of action reveal similar patterns of growth inhibition based on their log~10~IC~50~. This correlation was used to develop an automated algorithm based on the Pearson correlation rank test. The details of the COMPARE methodology have been described ([@B103], [@B102]; [@B143]). The use of the COMPARE algorithm to analyze data from the NCI human tumor cell line screen emerged more and more as a standard tool in drug discovery.

COMPARE analysis can be applied to identify inhibitors for a given mechanism of interest (e.g., inhibitors of EGFR, tubulins, DNA topoisomerases and others) ([@B137]; [@B106]). Vice versa, COMPARE analyses can also be used to suggest possible modes of action and/or determinants of resistance for compounds of interest (e.g., *P*-glycoprotein, p53 or Ras) ([@B75]; [@B1]; [@B70]; [@B100]).

COMPARE analyses were performed with software implemented into the web site of the NCI^[3](#fn03){ref-type="fn"}^. COMPARE analyses yielded rank-ordered lists of compounds. To obtain COMPARE rankings, a scale index of similarity between log~10~IC~50~ values of As~2~O~3~ and the transcriptome-based mRNA-based gene for the NCI panel of cell lines has been generated. The mRNA microarray hybridization of the NCI cell lines has been reported and deposited at the NCI Web site^4^ ([@B116]; [@B3]).

COMPARE analyses were performed to produce rank-ordered lists of genes expressed in the NCI cell lines. The results are sorted by the correlation coefficient (*R*-values). The methodology has been described previously in detail as a tool to identify candidate genes for drug resistance and sensitivity ([@B34]; [@B35]; [@B89]). Greater mRNA expression correlated with enhanced drug resistance in the standard COMPARE approach, whereas greater mRNA expression in cell lines indicated drug sensitivity in reverse COMPARE analyses. Pearson's correlation test was used to calculate significance values and rank correlation coefficients as a relative measure for the linear dependency of two variables.

### Hierarchical Cluster Analyses

Another wide used methodology to extract relevant results from transcriptomic data sets are cluster analyses, which represent distance/proximity-based approaches to unravel structures in large data sets. In systems biology, cluster analyses are valuable to define profiles of genes ("gene signatures"), whose expression is linked to biological phenomena, i.e., histological subtypes of tumors, resistance or sensitivity of tumors toward anticancer treatments, survival chances of cancer patients etc. Among the numerous clustering methods (e.g., topological interaction models, influence maps, physical regulatory maps, self-organizing maps, principal component analysis etc.), supervised, hierarchical and aggregative techniques provide advantages for pharmacological questions in cancer biology and pharmacology, because of their flexibility, possibility to include biological knowledge with different weighting, and detection of higher-order relationships between clusters of profiles ([@B97]). Aggregative hierarchical clustering represents a frequently method to investigate gene expression signatures ([@B33]; [@B105]; [@B112]).

In the present study, we performed hierarchical cluster Analysis to group heterogeneous objects into clusters of homogeneous objects. All objects are assembled into a cluster tree (dendrogram). Thus, objects with tightly related features appear together, whereas the separation in the cluster tree increases with progressive dissimilarity. The merging of objects with similar features leads to formation of a cluster, the shortest the distance of the branch the closest degree of relatedness ([@B60]). Hierarchical clustering and heat map analysis were conducted using clustered image map (CIM) miner software. One matrix CIM^[4](#fn04){ref-type="fn"}^ and Ward method were performed. Importantly, COMPARE analyses and cluster models have been validated for gene expression profiling, identification of candidate genes for drug resistance and sensitivity and for understanding molecular biology of cancer ([@B27]; [@B116]).

### Interactome Network Analysis

The biomedical literature has been flooded with genomic and transcriptomic data, which urgently need to be organized in bioregulatory networks comparable to electronic circuit programs. The rationale to generate regulatory network models is that pathophysiological processes may be associated with unexpected traits that are not amenable to standard statistical techniques. Building reliable regulatory networks from large-scale genomic and transcriptomic will considerably improve the identification of novel signaling routes and therapeutic targets, since both may differ in healthy and diseased cells ([@B76]). Hence network approaches will be indispensable for patient-tailored precision medicine to predict drug response and overcome drug resistance ([@B40]).

Therefore, a number of software programs have been developed to address this problem, including programs developed at academia such as network molecular interaction maps (MIMs) ([@B66], [@B67]; [@B68],[@B69]; [@B88]), Cytoscape, ([@B55]), CellDesigner ([@B39]), TranscriptomeBrowser ([@B85]; [@B77]), PathVisio-Validator ([@B17]), Systems Biology Graphical Notation ([@B90]) as well as commercial products, e.g., Biocarta, Ingenuity Pathway analysis, Pathway Studio, MetaCore and many others. All these programs reveal advantages and disadvantages ([@B126]; [@B133]).

In the present investigation, genes described in the literature as factors determining cellular responsiveness to As~2~O~3~ (**Table [5](#T5){ref-type="table"}**) plus the genes identified via compare analysis of our present and previous investigations on As~2~O~3~ ([@B32]) were chosen to perform network analyses using Ingenuity Pathway Analysis (IPA) (Qiagen Bioinformatics, Redwood City, CA, United States), as IPA is one of the most used programs to generate bioregulatory networks. We performed network analysis using two different approaches: manually curated pathways and software-based analyses. Published information from literature was used to generate the network and to cluster the genes. IPA Pathway Designer was used to construct the network and the pathways where our genes contributed to.

### Gene Promoter Transcription Factor Motif Analysis

Forty genes from the COMPARE analyses results significantly associated with log~10~IC~50~ values of As~2~O~3~ for the 58 cell lines. UCSC Genome Browser Gene^[5](#fn05){ref-type="fn"}^ was used to analyze the 40 genes to obtain gene's promoter sequences up to 50 kilobases upstream of the transcription start site. The results were saved on BED (Browser Extensible Data) files for further use ([@B118]).

The bed file was uploaded on Galaxy, Cistrome software ([@B84]) to detect the possible transcription factor binding motifs for the selected genes. The software is available at <http://cistrome.dfci.harvard.edu/ap/root>. Integrative analysis using SeqPos tool was applied to screen the motif binding site on the uploaded genes promoter sequences. Both, UCSC Genome Browser and Galaxy, Cistrome are free softwares. SeqPos tool scans all the motifs that are available on the following databases Transfac, JASPAR, UniPROBE (pbm), hPDI database. The result of the screening was ordered by -log~10~ (*P*-value).

Statistical Analysis
--------------------

Pearson's correlation test was applied to calculate significance correlation in COMPARE and hierarchical cluster analyses. The chi-squared test was performed to investigate the linear dependency between the resistance and the sensitivity of the cell lines panel. Student's *t*-test (Microsoft Excel 2016) was applied to determine the statistical significance of As~2~O~3~ effect on AP-1 and NF-κB transcription factors. A level of *P* \< 0.05 was revealed as statistically significant. All data were shown as mean values ± SD.

Results
=======

Cytotoxicity
------------

The cytotoxic effect of As~2~O~3~ was determined using resazurin reduction assay. As~2~O~3~ was applied on three different resistance mechanisms (*P*-glycoprotein overexpression, mutant EGFR, knockout p53). The IC~50~ values for CCRF-CEM cells and CEM/ADR5000 cells were 0.48 ± 0.22 μM and 0.90 ± 0.38 μM, respectively. For CEM/ADR5000 the degrees of resistance was 1.88. Additionally, As~2~O~3~ was tested against HCT116 p53 knockout cells (p53^-/-^) and their wild-type cells, HCT116 (p53^+/+^). The HCT116 (p53^-/-^) cells exhibited resistance toward As~2~O~3~ with an IC~50~ value of 90.83 ± 0.83 μM, which was higher than the IC~50~ value of wild-type HCT116 (p53^+/+^) cells (12.68 ± 0.78 μM). Interestingly, glioblastoma cell line (U87.MG) were even more sensitive to As~2~O~3~ than U87.MG wild-type cells with IC~50~ values of 15.60 ± 0.93 and 47.82 ± 1.25 μM, respectively. The degree of resistance was 0.33. The Dose response curves and IC~50~ values for the above-mentioned cell lines are shown in **Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**.

![Growth inhibition of sensitive and drug-resistance cancer cell lines treated with different concentrations of As~2~O~3~. **(A)**. CCRF-CEM and *P*-glycoprotein-expressing CEM/ADR5000 leukemia cell lines; **(B)** HCT-116 (p53^+/+^) wild-type and HCT-116 (p53^-/-^) knockout colon carcinoma cell lines; **(C)** U87.MG wild-type and EGFR-transfected U87.MG ΔEGFR glioblastoma cell lines. The dose response curves show mean values ± SD of three independent experiments with each six parallel measurements.](fphar-09-00143-g001){#F1}

###### 

IC~50~ values of As~2~O~3~ toward various tumor cell lines.

  Cell lines          As~2~O~3~      
  ------------------- -------------- ------
  CCRF-CEM            0.48 ± 0.22    1.88
  CEM/ADR5000         0.90 ± 0.38    
  U87.MG              47.82 ± 1.25   0.33
  U87.MG ΔEGFR        15.60 ± 0.93   
  HCT116 (p53^+/+^)   12.68 ± 0.74   7.16
  HCT116 (p53^-/-^)   90.83 ± 0.83   

The data is shown as mean values ± SD of three independent experiments with each six parallel measurements. Degrees of resistance were calculated by dividing the IC

50

value of resistant cell line over the IC

50

value of sensitive cell line.

COMPARE and Hierarchical Cluster Analyses
-----------------------------------------

The transcriptome-wide mRNA expression of the 58 NCI cell lines were subjected to COMPARE analyses based on Pearson's rank correlation tests. In this test, the microarray expression data were correlated with the log~10~IC~50~ values of As~2~O~3~ for the 58 cell lines. This bioinformatics approach permitted the identification of molecular factors that liked to cellular response to As~2~O~3~. The top 20 genes with positive correlation coefficients and top 20 genes with negative correlation coefficients are shown in **Table [2](#T2){ref-type="table"}**. These 40 genes were used to conduct hierarchical cluster analysis (cluster image mapping) to predict, whether these genes may play a role in sensitivity or resistance of the cells to As~2~O~3~. The resulting dendrogram with the 58 cell lines applied cluster analyses depicted on the left of the heat-map, while distribution of the 40 genes are shown on the top of the heat-map (**Figure [2](#F2){ref-type="fig"}**). The dendrogram can be divided into four major clusters for As~2~O~3~. Based on chi-square test we looked whether the clustering of cell was associated with cellular responsiveness of the cell lines to As~2~O~3~. Indeed, the branching of sensitive or resistant cell lines was statistically significant (**Table [3](#T3){ref-type="table"}**). The genes identified via this approach belong to diverse groups such as cell cycle progression and proliferation genes including (*PRKACA*, ARHGAP19, *CDKN2D* etc.), tumor suppressor related genes (*RBBP4, CHMP1A*, and *GPRC5A*), cytoskeleton related genes (*PTPRC, ABLIM1, EPB41L1* and *PLS1*), metabolic pathway genes (*ME1, COASY*, and *ALDH3A2*), signal transduction genes (*PPAP2C* and *PKP3*) and apoptosis-regulating gene (ID1).

###### 

Correlation coefficients of mRNA expression to log~10~ IC~50~ values identified by COMPARE analyses for 58 NCI tumor cell lines and functions of the identified genes.

  Coefficient   Symbol      Name                                                                     Function
  ------------- ----------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  0.568         *PRKACA*    Protein kinase, cAMP-dependent, catalytic, α                             Affects cell cycle progression and proliferation by downregulation of CDKN1B.
  0.507         ARHGAP19    Rho GTPase activating protein 19                                         Involved in cell migration, proliferation, actin remodeling, differentiation, and G1 cell cycle progression.
  0.487         *CAMK4*     Calcium/calmodulin-dependent protein kinase IV                           Role in spermatogenesis by phosphorylating protamines.
  0.485         *BTN2A1*    Butyrophilin, subfamily 2, member A1                                     Involved in cell proliferation and development.
  0.483         *SEPT6*     Septin 6                                                                 Involved in cytokinesis
  0.475         *ITGA4*     Integrin, α 4 (antigen CD49D, α 4 subunit of VLA-4 receptor)             Cell surface adhesion receptor mediating cell-adhesion to extracellular matrix or to other cells.
  0.475         *CNTRL*     Centrosomal protein 110 kDa                                              Involved in cell cycle progression and cytokinesis.
  0.471         *DNAJC8*    Platelet-activating factor receptor                                      Unknown
  0.47          *SPDEF*     SAM pointed domain containing ets transcription factor                   Tumor metastasis suppressor.
  0.47          *RYR3*      Ryanodine receptor 3                                                     Calcium release from intracellular storage.
  0.469         *IKZF1*     IKAROS family zinc finger 1 (Ikaros)                                     Implicated in the control of lymphoid development.
  0.467         *ACTR2*     ARP2 actin-related protein 2 homolog (yeast)                             Role for cell shape and motility.
  0.463         *PTPRC*     Protein tyrosine phosphatase, receptor type                              Structural constituents of cytoskeleton, involved in cell organization/biogenesis.
  0.459         *PRIM2*     Primase, DNA, polypeptide 2 (58 kDa)                                     DNA primase subunit, key enzyme in DNA replication.
  0.457         *RBBP4*     Retinoblastoma binding protein                                           Inhibitor of TGFB1 activity, plays a role in oncogenesis.
  0.454         *PRR3*      Proline rich 3                                                           Nucleic acid binding activity.
  0.452         *CDKN2D*    Cyclin-dependent kinase inhibitor 2D (p19)                               Cell growth regulator controlling G1 cell cycle progression.
  0.452         *ARHGEF6*   Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6                     Activator of Ras-like family of Rho proteins by exchanging bound GDP for GTP.
  0.45          *NDC80*     NDC80 homolog, kinetochore complex component (*S. cerevisiae*)           Component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity.
  0.448         VCY         Variable charge, Y-linked                                                May mediate spermatogenesis processes or may contribute to sex ratio distortion.
  0.435         *IRF2*      Interferon regulatory factor 2                                           Repressor of IRF1, transcriptional activator of histone H4, regulates NFκB activity.
  -0.71         *PPAP2C*    Phosphatidic acid phosphatase type 2C                                    Converts phosphatidic acid to diacylglycerol, function in *de novo* synthesis of glycerolipids phospholipase D-mediated signal transduction.
  -0.566        *ALDH3A2*   Aldehyde dehydrogenase 3 family, member A2                               Catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids.
  -0.542        *ME1*       Malic enzyme 1, NADP^+^-dependent, cytosolic                             Mitochondrial NAD-dependent malic enzyme, catalyzing the oxidative decarboxylation of malate to pyruvate.
  -0.539        *COASY*     CoA synthase                                                             Coenzyme A (CoA) is a carrier of acetyl and acyl groups in cells and is crucial for numerous metabolic pathways.
  -0.533        *PKP3*      Plakophilin 3                                                            Mediating protein-protein interactions. Playing a role in junctional plaques.
  -0.531        *ID1*       Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein   Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation.
  -0.517        *GPRC5A*    G protein-coupled receptor, family C, group 5, member A                  Functions as a tumor suppressor in lung cancer. May play a role in the proliferation of breast cancer cells.
  -0.513        *TST*       Thiosulfate sulfurtransferase (rhodanese)                                May contribute to cyanide detoxification.
  -0.496        *ABLIM1*    Actin binding LIM protein 1                                              Putatively bridging the actin-based cytoskeleton with LIM protein-binding partners.
  -0.493        *CPD*       Carboxypeptidase D                                                       Carboxypeptidase, involved in secretory pathways.
  -0.487        *CHMP1A*    Chromatin modifying protein 1A                                           Role in nuclear gene silencing, tumor suppressor, regulates tumor growth by the TP53 signaling pathway.
  -0.486        *GFPT1*     Glutamine--fructose-6-phosphate transaminase 1                           Involved in regulating the availability of precursors for *N* and *O*-linked glycosylation of proteins.
  0.483         *EPB41L1*   Erythrocyte membrane protein band 4.1-like 1                             Critical for the membrane-associated cytoskeleton structure of erythrocytes.
  -0.48         *TACC2*     Transforming, acidic coiled-coil containing protein 2                    Playing a role in organizing centrosomal microtubules, tumor progression marker.
  -0.479        *INPP1*     Inositol polyphosphate-1-phosphatase                                     Involved in response to lithium prophylaxis and treatment of bipolar disorders.
  -0.477        *MST1R*     Macrophage stimulating 1 receptor (c-met-related tyrosine kinase)        Involved in development of epithelial tissue as well as cell proliferation, cell survival, and cell motility in both normal and disease states.
  -0.476        *PLS1*      Plastin 1                                                                Actin-bundling protein in the absence of calcium.
  -0.475        *KRT8*      Keratin 8                                                                Role in maintaining cellular structural integrity.
  0.475         *GULP1*     GULP, engulfment adaptor PTB domain containing 1                         Adaptor protein required for efficient engulfment of apoptotic cells by phagocytes.

![Heat map obtained by cluster analysis from microarray-based mRNA expression profiles of genes correlating with cellular responsiveness to As~2~O~3~. The analysis shows the clustering of 58 NCI tumor cell lines.](fphar-09-00143-g002){#F2}

###### 

Separation of clusters of NCI cell lines obtained by hierarchical cluster analyses for As~2~O~3.~

                              Sensitive             Resistant
  --------------------------- --------------------- -----------
  AS~2~O~3~                                         
  Partition (log~10~IC~50~)   \<-5.45 M             \>-5.45 M
  Cluster 1                   6                     17
  Cluster 2                   0                     7
  Cluster 3                   18                    5
  Cluster 4                   5                     0
  χ^2^ Test                   *P* = 1.86 × 10^-5^   
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was used as a cut-off to separate cancer cell lines as being "sensitive" or "resistant."

Gene Promoter Analysis for Transcription Factor Binding Motifs
--------------------------------------------------------------

Using the computational method of Galaxy Cistrome analysis, we investigated DNA promoter sequences of deregulated genes found in NCI microarray data. Forty genes were uploaded to Galaxy Cistrome for SeqPos motif scan. These genes are contribute in cell cycle progression and proliferation, cytokinesis, metabolic pathways, cell shape, apoptosis and signal transduction. The top 20 pronounced motifs are illustrated in **Table [4](#T4){ref-type="table"}**. Interestingly, AP-1 and NF-κB were among the top transcription factors that possibly bind to the promoters with *z*-scores of -5.456 and -5.268, respectively. Both factors play critical role in the cancer therapy.

###### 

Top 20 transcription factor promoter binding motifs for genes identified by COMPARE analysis (see **Table [3](#T3){ref-type="table"}**).

  Clusters   Factor         *z*-score    -10^∗^log(*p*-value)
  ---------- -------------- ------------ ----------------------
  1          YY1            **-**7.388   302.304
             Zfp42          **-**6.184   218.837
  2          PIF3           **-**6.798   259.645
             Tye7           **-**3.945   101.291
  3          JUND           **-**6.447   235.883
             **AP-1**       **-**5.456   175.291
             AP-1           **-**5.034   152.444
             AP-1           **-**4.834   142.187
             AP-1           **-**4.286   116.074
             GCN4           **-**4.208   112.612
             BACH2          **-**3.219   73.482
  4          Hic1           **-**5.884   200.294
  5          EBF1           **-**5.841   197.699
  6          MYB            **-**5.793   194.848
             Myb            **-**3.468   82.468
  7          REB1           **-**5.788   194.519
  8          STAT1          **-**5.636   185.601
  9          Ets1           **-**5.585   182.653
  10         Ets1           **-**4.274   115.545
             Ets1           **-**4.047   105.592
             ELK4           **-**3.344   77.908
             Etv5           **-**3.298   76.284
             Etv4           **-**3.135   70.602
             TAF-1          **-**5.508   178.251
  11         HBP-1a         **-**4.112   108.405
             TAF-1          **-**3.659   89.741
             CPRF-1         **-**3.21    73.169
             LTF            **-**5.483   176.81
  12         NEUROD1        **-**5.445   174.695
  13         MYF            **-**3.482   82.983
             Myf            **-**3.482   82.983
             LMO2           **-**5.319   167.711
  14         Tcfe2a         **-**5.29    166.101
             AREB6\| ZEB1   **-**4.582   129.833
             ATOH1          **-**3.199   72.778
             **NF-κB**      **-**5.268   164.89
  15         **NF-κB**      **-**4.056   105.966
             P50:P50        **-**3.365   78.671
             MZF1_1-4       **-**5.19    160.702
  16         Churchill      **-**3.25    74.581
             UBP1           **-**5.046   153.04
  17         S8\| Prrx2     **-**5.034   152.432
  18         Msx-2          **-**4.391   120.844
             Gbx2           **-**3.887   98.882
             Msx2           **-**3.79    94.95
             HOXD1          **-**3.298   76.274
             Barx-2         **-**3.192   72.547
             Prrx2          **-**3.191   72.514
             SP3            **-**5.015   151.433
  19         TIMELESS       **-**5.014   151.355
  20         Egr\| Egr1     **-**4.994   150.332

The binding motifs have been identified using Galaxy Cistrome.

AP-1 Reporter Assay
-------------------

Based on this finding, we assume that As~2~O~3~ may affect AP-1. To verify this hypothesis, we generated an AP-1 reporter cell line. The transfected HEK293 was incubated with five different concentrations of As~2~O~3~ to find out, whether AP-1 promoter activity was inhibited. Treatment of transfected cells with As~2~O~3~ significantly inhibited the PMA-mediated AP-1 activity in a dose-dependent manner as shown in **Figure [3](#F3){ref-type="fig"}**.

![Effect of As~2~O~3~ on transfected HEK-293 cells with an AP1 luciferase reporter construct. The AP1 reporter cell line was treated with five different concentrations of As~2~O~3~. The quantification was done after 24 h incubation in comparison to untreated control cells (CT). Mean value standard deviation of triplicate measurements are shown. ^∗^Indicates statistical significant in compare to control cells at level of *P* \< 0.05.](fphar-09-00143-g003){#F3}

NF-κB Reporter Assay
--------------------

Interestingly, the capability of As~2~O~3~ to affect NF-κB is debatable point in the literature. As~2~O~3~ can act as activator or inhibitor NF-κB ([@B136]; [@B48]). From our motif analysis, we obtained NF-κB among the top 20 transcription factors. Therefore, we investigated whether As~2~O~3~ is able to inhibit NF-κB signaling. To achieve this, we performed a SEAP-driven NF-κB reporter cell line. Indeed, As~2~O~3~ inhibit NF-κB in a comparable manner as the NF-κB inhibitor, triptolide. The fold change was statistically significant for three As~2~O~3~ concentrations (10, 15, and 50 μM) as demonstrated in **Figure [4](#F4){ref-type="fig"}**.

![Effect of As~2~O~3~ on NF-κB activity. The HEK-Blue^TM^ cell line was treated with four different concentrations of As~2~O~3~ or 1 μM triptolide (TP) as positive control. The quantification was done after 1 h incubation in comparison to untreated control cells (CT). Mean value standard deviation of triplicate measurements are shown. ^∗^Indicates statistical significant in compare to control cells at level of *P* \< 0.05.](fphar-09-00143-g004){#F4}

Interactome Network Analysis
----------------------------

For network analysis, we subjected the transcriptomic data of our present and previous investigations on As~2~O~3~ ([@B32]) as well as of factors determining cellular responsiveness to As~2~O~3~, which are known from the literature. In addition to the well-known target of As~2~O~3~ in APL, the PML-RARAα fusion protein ([@B44]; [@B127]; [@B20]; [@B86]; [@B82]), numerous other determinants of resistance have been described in the literature (**Table [5](#T5){ref-type="table"}**). Firstly, we performed a manually curated analysis of the genes by visual inspection of the genes and assigning then to their specific functions. The main functional groups were oxidative stress response, DNA repair, regulation of cell cycle/proliferation, signal transduction, drug transporter, cytoskeletal elements, tumor suppressors/oncogenes, metabolic pathways, and apoptosis. Based on this analysis, a presumable integrative interaction network was constructed (**Figure [5](#F5){ref-type="fig"}**).

###### 

Compilation of determinants of cellular responsiveness of cancer cells toward As~2~O~3~.

  Genes/Proteins                              Reference
  ------------------------------------------- ---------------------------------------------------------
  **Oxidative stress response:**              
                                              Present investigation;
  GSH                                         [@B139]; [@B24]; [@B52]; [@B74]; [@B49]; [@B92]; [@B93]
  *SOD (Cu/Zn)*                               [@B52]
  *NXN, TXNRD1*                               [@B32]
  *BACH2*                                     [@B151]
  γ-glutamyltransferase                       [@B43]
  HO-1                                        [@B151]
  HIF-1α                                      [@B128]; [@B81]
  GST-π                                       [@B148]
  **Drug transport:**                         
  *ABCC1 (MRP1);ABCC2 (MRP2); ABCC4 (MRP4*)   [@B119]; [@B19]; [@B142]
  *ASAN1*                                     [@B19]
  **DNA repair:**                             
  *SMC2L1*                                    [@B32]
  hMSH2                                       [@B52]
  **Cell cycle/proliferation:**               
  *ARHGAPAP19, CDKN2D, PRKACA*,               Present investigation
  *TFDP2, ZNF151*                             [@B32]
  *p21WAF/CIP*                                [@B52]
  *BTBD2, IGFBP1*                             [@B151]
  *CCND1*                                     [@B113]
  AURKB                                       [@B141]
  **Tumor suppressors/oncogenes:**            
  *RBBP4, CHMP1A, GPRC5A*                     Present investigation
  PML/RARAα                                   [@B44]; [@B127]; [@B20]; [@B86]; [@B82]
  p53                                         [@B138]; [@B146]; [@B150]
  EGFR                                        [@B144]
  *MYC*                                       [@B52]
  **Signal transduction:**                    
  *CAMK4, PPAP2C, PKB3*                       Present investigation
  AP-1 (Fos/Jun)                              Present investigation
  *DDEF2, SDC1, SH2BP3, STMN1, TJP1*          [@B32]
  PI3K, PKC, AKT                              [@B125]; [@B113]; [@B141]; [@B2]
  NFKB1                                       [@B32]
  **Metabolic pathways:**                     
  *ME1, COAS4, ALDH3A2*                       Present investigation
  *ALDH3A2*                                   [@B32]
  *ALDH3A1*                                   [@B145]
  **Cytoskeleton:**                           
  *PTPRC, ABLIM1, EPB41L1, PLS1*              Present investigation
  *ACAA2, ARHGEF7, KRT8, MYL3*                [@B32]
  **Apoptosis:**                              
  *ID1*                                       Present investigation
  *GRB7, PIGPC1*                              [@B32]
  Bcl2, Noxa                                  [@B52]; [@B93]
  Mcl-1                                       [@B2]

![Synopsis of mechanisms involved in the activity of As~2~O~3~ against cancer cells.](fphar-09-00143-g005){#F5}

As a second step, we subjected the assembled genes to Ingenuity Pathway Analysis. The interactome map obtained was rather complex (**Figure [6](#F6){ref-type="fig"}**). Therefore, we refined the analysis by analyzing the canonical pathways. The identified pathways belonged to signal transduction (phospholipase C signaling, protein kinase A signaling, signaling by Rho family GTPases, actin cytoskeleton signaling), molecular mechanisms of cancer, neurological pathways (axonal guidance signaling, neuroregulin signaling, agrin interactions with neuromuscular junctions), PXR/RXR activation, IL-7 signaling pathway and androgen signaling (**Figure [7](#F7){ref-type="fig"}**). The significance of this pathway are presented as --log (*p*-value) in **Figure [8](#F8){ref-type="fig"}**.

![Network pharmacology for genes determining cellular responsiveness to As~2~O~3~ using Ingenuity Pathway Analysis. Dashed and solid lines indicates indirect and direct interactions, respectively.](fphar-09-00143-g006){#F6}

![Canonical pathway analysis for genes determining cellular responsiveness to As~2~O~3~ using Ingenuity Pathway Analysis.](fphar-09-00143-g007){#F7}

![Pathways identified by IPA. Significance *P*-values were calculated based on the Fisher's right tailed exact test. The --log (*p*-value) are shown on the *y*-axis of the bar chart. The color of the bars indicates the activity (orange bars) or the inhibition (blue bars) of the predicted pathways. In this analysis only significant results was shown. By default IPA applies a --log (*p*-value) cutoff of 1.3 (threshold). Pathways with a *p*-value equal to or greater than (less significant than) 0.05 are not shown. The orange and blue colored bars indicate predicted pathway activation, or predicted inhibition, respectively (*z*-score). White bars are those with a *z*-score at or very close to 0. Gray bars indicate pathways, where no prediction can currently be made.](fphar-09-00143-g008){#F8}

In addition, cell death and survival, cell cycle, cell morphology, cellular movement, cellular development were identified by IPA as biological functions from our selected genes (**Figure [9](#F9){ref-type="fig"}**). A network of 36 selected genes that involve in the cell death (apoptosis) as the top biological function is shown in **Figure [10](#F10){ref-type="fig"}**.

![Statistically significant biological function analysis using IPA.](fphar-09-00143-g009){#F9}

![Set of 43 genes that involve in cell death function. This gene is duplicated on the inserted dataset.](fphar-09-00143-g010){#F10}

While the importance of signaling processes was obvious by both visually and IPA-guided analyses, both approaches revealed additional functional groups complementing each other and highlighting the complexity of mechanisms contributing to the cytotoxicity of As~2~O~3~.

Discussion
==========

In the current study, we investigated the potential of As~2~O~3~ to treat drug-resistant tumor cells. Tumors frequently develop resistance to a broad spectrum of anti-cancer drugs ([@B29]). Therefore, drug resistance represents an important obstacle to defeat cancer. In this study, we showed that As~2~O~3~ revealed profound cytotoxicity toward various cancer cell lines.

Our results showed that multidrug-resistant CEM/ADR5000 cells which overexpress *P*-glycoprotein did not reveal cross-resistance to As~2~O~3~. Therefore, *P*-glycoprotein did not play an important role for resistance cellular responsiveness to As~2~O~3~. Our results are in accordance with those of ([@B53]), who also did not find cross-resistance of multidrug-resistant *P*-glycoprotein-expressing cell lines toward As~2~O~3~. This finding is also corroborated by data generated by [@B120]. As~2~O~3~ counteracted multidrug resistance by interference with drug resistance genes. The expression of DNA topoisomerase 2 was increased and of glutathione S-transferase-π and Bcl-2 decreased upon treatment with As~2~O~3~ ([@B148])~.~ Other ATP-binding cassette (ABC) transporters than *P*-glycoprotein might be more important for As~2~O~3~. Treatment with As~2~O~3~ lead to the induction of ABCC1, but not *P*-glycoprotein ([@B119]) and As~2~O~3~-resistant cell lines overexpressed *P*-glycoprotein but also ABCC1, ABCC2, and ABCC4 ([@B19], [@B18]; [@B142]). ABCC1-overexpressing tumor cells accumulated less As~2~O~3~ than wild-type cells ([@B115]).

To the best of our knowledge, the anti-proliferative activities of As~2~O~3~ and particularly its effect against p53 knockout HCT116 (p53^-/-^) colon carcinoma and EGRF mutant U87.MG ΔEGFR glioblastoma multiforme cell lines are being tested for the first time.

TP53 maintains cellular integrity by regulating cell cycle arrest, DNA repair and apoptosis. Functional loss by TP53 mutations lead not only to carcinogenesis, but to drug and radio resistance too ([@B51]). In our investigation, HCT116 (p53^-/-^) knockout cells exhibited resistance toward As~2~O~3~. Our data are in agreement with other investigations with isogenic cell lines ([@B138]; [@B146]), but not with cell lines with different p53 status and different genomic background ([@B83]; [@B149]). This indicates that the p53 mutational status in correlation studies with different cell lines may be overruled by other mechanisms of resistance to As~2~O~3~. Therefore, the targeted loss of p53 function by knockout was more suitable to undoubtedly elucidate the role of p53 as resistance factor for As~2~O~3~. A role of p53 mutations can also be deduced from cells resistant to As~2~O~3~, which acquired p53 mutations and which were re-sensitized to As~2~O~3~ by a small molecule inhibitor specifically targeting mutant p53, nutlin-3 ([@B150]).

Furthermore, we found that U87.MG cells showed collateral sensitivity to As~2~O~3~. EGFR plays a significant role in cancer progression, not only by transducing growth signals into cancer cells, but also by triggering invasion and metastasis ([@B6]; [@B87]). Inhibition of EGFR leads to the induction of apoptosis. This may explain, how As~2~O~3~ suppresses EGFR-expressing tumor cells ([@B32]). The phenomenon of collateral sensitivity (hypersensitivity) offers an attractive strategy to overcome drug resistance ([@B107]). Moreover, collateral sensitivity may open the chance for combination therapy of known anticancer drugs with As~2~O~3~ to efficiently kill drug- resistant tumors with EGFR over expression. The reason for the collateral sensitivity is not yet known, but a direct interaction of As~2~O~3~ with EGFR could be suggested, since it has been reported that As~2~O~3~ down-regulated EGFR expression in a dose-dependent manner ([@B144]).

We further evaluated the molecular factors of sensitivity and resistance of cancer cell lines toward As~2~O~3~. We correlated the log~10~IC~50~-values with the microarray- based mRNA expression profiles of 58 tumor cell lines by COMPARE analysis. Genes from diverse functional groups have been identified. Previously, the effect of As~2~O~3~ on mRNA expression profile of NCI cell line panel have been reported ([@B32]; [@B120]). Here, we focused on the Novartis microarray platform. In all studies the chi-square test reveal a significant clustering of the cell lines based on their sensitivity or resistance toward As~2~O~3~. Moreover, several biological functions of the genes, e.g., cell cycle progression, and proliferation related genes, signal transduction and apoptosis-regulating gene were common in the previous and the present investigations.

Interestingly, the transcription factors binding motif analysis revealed two transcription factors (NF-κB and AP-1) which are closely connected not only to carcinogenesis but also with drug resistance ([@B11]). Therefore, we evaluated the potential of As~2~O~3~ to inhibit the activity of both AP-1 and NF-κB. NF-κB and AP-1 regulate numerous important cellular processes. NF-κB activity is regulated by IκB kinase, which phosphorylates the NF-κB inhibitor IκB. Fos is key constituent of AP-1 and is regulated by serum responsive factors (SRFs) as well as ternary complex factors (TCFs). AP-1 regulates cellular growth, differentiation, program cell death, transformation and invasion ([@B94]; [@B124]; [@B14]). AP-1 complexes, particularly those that contain c-Jun, achieve their growth promoting function via repression of tumor suppressor genes, such as p53, p21cip1/waf1 and p16 ([@B121]). Although NF-κB and AP-1 are two distinct regulatory mechanisms, they may modulate each other ([@B38]).

Our results that As~2~O~3~ inhibited the DNA-binding activity in a reporter cell model are in accordance with other reports demonstrating that As~2~O~3~ inhibited NF-κB activity ([@B48]; [@B134]; [@B91]; [@B42]). The ectopic expression of NF-κB p65 protected cells from As~2~O~3~ induced apoptosis ([@B42]), indicating that the NF-κB pathway mediates resistance to As~2~O~3~.

Activator protein 1 (AP-1) is a transcription factor belongs to the group of *trans*-acting elements that consist of several proteins, including JUN, FOS, ATF (activating transcription factor) and MAF (musculoaponeurotic fibrosarcoma). AP-1 forms homodimers or heterodimers via its leucine-zipper domains, different dimerization ultimately allow that AP-1 recognizes different sequences in the promoters and enhancers of target genes ([@B26]). The AP-1 activity was causatively linked to cell transformation and it assumed to be a significant factor for tumorigenesis ([@B63]). Therefore, AP-1 might provide opportunities for the development of novel targeted cancer treatment strategies ([@B5]; [@B95]; [@B63]). Interestingly, AP-1 drives not only carcinogenesis, but also increases the expression of multidrug resistance-conferring *MDR1* gene ([@B23]). Therefore, c-Jun is a potential drug target to combat MDR ([@B101]).

Using an AP-1-specific reporter cell line, we found that As~2~O~3~ inhibited AP-1 activity. This result fits to data of ([@B140]), who observed that the As~2~O~3~-induced cell cycle arrest was correlated with repression of c-Fos (as component of the AP-1 heterodimeric complex). In another study, As~2~O~3~ treatment also downregulated c-Fos expression ([@B131]). The second partner of AP-1, c-Jun, was more phosphorylated is As~2~O~3~-resistant cells and hypophosphorylated in As~2~O~3~-sensitive cells upon As~2~O~3~ treatment ([@B113]).

Nuclear factor (NF-κB) is another transcription factor responsible for expression regulation of genes involve in apoptosis, drug resistance, innate and adaptive immune responses, proliferation and metastasis ([@B46]). It exists as inactive form in the cytoplasm by interacting with inhibitory proteins (IκB). Phosphorylation of IκB by IκB kinase (IKK) activates NF-κB. Then, NF-κB is translocated to the nucleus, where it binds to specific gene promoters to *trans*-activate the expression of target genes ([@B7]). NF-κB is constitutively active in hematologic malignancies and various types of solid tumors ([@B10]). Besides, cancer cells become resistant to antitumor drugs and irradiations by NF-κB activation ([@B7]). Furthermore, decreased expression of anti-apoptotic genes is correlated with inhibition of NF-κB ([@B80]). Taken together the inhibition of NF-κB represents a promising target for cancer prevention and therapy ([@B98]; [@B80]).

Several studies described that As~2~O~3~ exerts its anti-tumor activity by inhibiting AP-1 ([@B129]; [@B13]). However, other studies showed that As~2~O~3~ stimulated AP-1 activity in cultured human fibroblasts and APL ([@B16]; [@B57]). This contradiction points to the fact that many arsenic compounds reveal both anti-cancer and pro-cancer activates. In this study, we used HEK293 cell lines transfected with AP-1 luciferase reporter construct to detect the activity of AP-1 after As~2~O~3~ treatment. We showed that As~2~O~3~ inhibit AP-1 in dose- dependent manner and this in line with previous study in HeLa, CaSki, and C33A cells ([@B132]).

On the other hand, many suggestions have been put forth on the mechanisms, by which As~2~O~3~ cause apoptosis. One of the proposed explanations is that As~2~O~3~ inhibits the NF-κB activity. It induces genes involve in cell survival, tumor growth, blocking apoptosis and metastasis ([@B9]). NF-κB up-regulates both intracellular adhesion molecules and vascular cell adhesion, and inhibits IL-6 secretion resulting from adhesion of multiple myeloma cells to bone marrow stroma ([@B96]).

Our results from NF-κB reporter assays are in line with other studies demonstrating that As~2~O~3~ significantly inhibits NF-κB activity in a dose- dependent manner. In HL-60 cells, As~2~O~3~ suppressed the DNA-binding activity of the NF-κB heterodimer (p65/p50) through inhibiting the degradation of IκB-α and then preventing nuclear translocation of p65 and the binding of NF-κB with their target gene consensus sequences ([@B48]).

Although it is well known that natural products act rather in a multi-specific manner than mono-specifically against one single target ([@B28]), it turns out more and more that synthetic drugs and even targeted small molecules affect multiple targets and pathways in diseased cells ([@B41]). Therefore, network pharmacological approaches have been suggested to provide a more comprising picture of what is happening in cell upon drug treatment ([@B108]). Hence, network pharmacology represents a valuable tool to investigate the mode of action of both synthetic and natural compounds. A conclusion that can be drawn from our network analysis of As~2~O~3~ is that rather entire gene clusters belonging to specific pathways and functional groups than single genes were involved in drug action. Given the individual differences of organisms and the biological flexibility to adapt to xenobiotic exposures, it is reasonable from an evolutionary point of view to assume cellular and molecular reactions of high flexibility and plasticity. The concept of the past ("one drug -- one target") obviously needs to be revisited and enlarged by a "one drug -- multiple pathway" hypothesis.

The international sequencing projects (e.g., Cancer Genome Atlas,) unraveled a huge diversity of mutational profiles and gene expression patterns in individual tumors ([@B21]). Hence, it is reasonable that each patient's tumor might react in a different manner to chemotherapy. In the case of As~2~O~3~, we found several major functional groups using manual curated network analysis to be involved in cellular responsiveness to the drug, i.e., oxidative stress response, DNA repair, regulation of cell cycle/proliferation, signal transduction, drug transporter, cytoskeletal elements, tumor suppressors/oncogenes, metabolic pathways, and apoptosis. On the other hand, we found many other important pathways using IPA network analysis, e.g., molecular mechanisms of cancer, axonal guidance signaling, signaling by Rho family GTPases, protein kinase A signaling, phospholipase signaling, actin cytoskeleton signaling etc. The manually curated and the IPA approaches revealed comparable findings for three types of pathways: signal transduction, metabolic pathways and cytoskeletal elements. Moreover, axonal guidance signaling, neuroregulin signaling and agrin interaction at neuromuscular junction pathways may demonstrate the neurotoxicity of As~2~O~3~. This is an interesting finding, since neurotoxicity is a known toxicity of arsenic ([@B130]). Our IPA analysis identified three canonical pathways that might explain neurotoxic effects of As~2~O~3~. Furthermore, neurological effects of arsenic may lead to cytoskeletal framework disorganization which is a suggested mechanism of arsenic-induced neurotoxicity ([@B130]). Interestingly, IPA network analysis also revealed several pathways which are directly connected with the cytoskeleton in addition to glioma signaling. It deserves further investigations, whether these pathways are also involved in the collateral sensitivity of the U87.MG. ΔEGFR glioblastoma cells to As~2~O~3~. Not surprisingly, IPA showed cell death and survival as top biological functions of the inserted genes with a *p*-value of 4.28E-09 and with 43 genes that contribute to this function.

Having the inter- and intra-tumor heterogeneity in mind, it is reasonable to assume that different tumors activate different genes belonging to the same main pathways and functional groups. The complexity of this process can be manage by network modeling, and corresponding bioinformatical tools are becoming more and more indispensable for pharmacology of both synthetic and natural drugs.

In conclusion, As~2~O~3~ was active against tumor cell lines. It showed collateral sensitivity toward U87.MG ΔEGFR. In addition to that, it inhibited AP-1 and NF-κB activity in a dose- dependent manner. COMPARE and cluster analyses using gene expression profiling of 58 NCI cell lines predicted the sensitivity or resistance of cancer cells to As~2~O~3~. Using a network pharmacological approach, we identified functional clusters of genes involved in the mechanisms of action in cancer cells.
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APL

:   acute promyelocytic leukemia

AP-1

:   activator protein 1

As~2~O~3~

:   arsenic trioxide

EGFR

:   epidermal growth factor receptor

NF-κB

:   nuclear factor-kappa in B cells

PMA

:   phorbol 12-myristate 13-acetate

PML

:   promyelocytic leukemia

RARA

:   retinoic acid receptor alpha

SEAP

:   secreted embryonic alkaline phosphatase

TNF

:   tumor necrosis factor
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